-
1.
公开(公告)号:US20240327834A1
公开(公告)日:2024-10-03
申请号:US18390233
申请日:2023-12-20
IPC分类号: C12N15/113 , A61K31/713
CPC分类号: C12N15/113 , A61K31/713 , C12N2310/11 , C12N2310/14 , C12N2310/321 , C12N2310/344 , C12N2310/3515
摘要: The invention relates to a double-stranded ribonucleic acid (dsRNA) targeting a Serum Amyloid A (SAA) gene, and methods of using the dsRNA to inhibit expression of SAA.
-
公开(公告)号:US20240287510A1
公开(公告)日:2024-08-29
申请号:US18213116
申请日:2023-06-22
发明人: Michael GANTIER
IPC分类号: C12N15/113 , A61K45/06 , C12N15/11
CPC分类号: C12N15/113 , A61K45/06 , C12N15/111 , C12N2310/11 , C12N2310/315 , C12N2310/321 , C12N2310/3231 , C12N2310/341 , C12N2310/344 , C12N2320/53
摘要: The present invention relates to oligonucleotides that maintain a Toll-Like Receptor 7 (TLR7) response and/or which potentiate Toll-Like Receptor 8 (TLR8) sensinq.
-
公开(公告)号:US20240271131A1
公开(公告)日:2024-08-15
申请号:US18185929
申请日:2023-03-17
发明人: Janne Juha TURUNEN , Antti AALTO , Bart KLEIN , Lenka VAN SINT FIET , Julien Auguste Germain BOUDET
IPC分类号: C12N15/113
CPC分类号: C12N15/113 , C12N2310/11 , C12N2310/344 , C12N2310/533 , C12N2320/34 , C12Y305/04004
摘要: The invention relates to antisense oligonucleotides that are capable of bringing about specific editing of a target nucleotide (adenosine) in a target RNA sequence in a eukaryotic cell, wherein said oligonucleotide does not, in itself, form an intramolecular hairpin or stem-loop structure, and wherein said oligonucleotide comprises a non-complementary nucleotide in a position opposite to the nucleotide to be edited in the target RNA sequence.
-
公开(公告)号:US12049627B2
公开(公告)日:2024-07-30
申请号:US17071473
申请日:2020-10-15
IPC分类号: C07H21/04 , C12N15/113
CPC分类号: C12N15/113 , C12N2310/14 , C12N2310/314 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/343 , C12N2310/344 , C12N2310/346 , C12N2310/321 , C12N2310/3521 , C12N2310/322 , C12N2310/3533
摘要: Provided are compositions and methods comprising two-tailed siRNAs (tt-siRNAs) that exhibit unprecedented cellular uptake and silencing. Also provided are methods of treating neurological and other diseases with the two-tailed siRNAs of the invention.
-
公开(公告)号:US20240110189A1
公开(公告)日:2024-04-04
申请号:US18023548
申请日:2021-08-27
申请人: VOR BIOPHARMA INC.
发明人: John Lydeard , Chong Luo , Michelle Lin , Jessica Evelyn Lisle
IPC分类号: C12N15/113 , C12N5/0789 , C12N9/22
CPC分类号: C12N15/1138 , C12N5/0647 , C12N9/22 , C12N2310/344 , C12N2510/00
摘要: This disclosure provides, e.g., novel cells having a modification (e.g., insertion or deletion) in the endogenous CLL1 gene. The disclosure also provides compositions, e.g., gRNAs, that can be used to make such a modification.
-
6.
公开(公告)号:US20240110180A1
公开(公告)日:2024-04-04
申请号:US18199390
申请日:2023-05-19
发明人: Brian Bettencourt , Kevin Fitzgerald , Stuart Milstein , Martin A. Maier , Klaus Charisse , Kallanthottathil G. Rajeev , Satyanarayana Kuchimanchi , Muthiah Manoharan , Tuyen M. Nguyen
IPC分类号: C12N15/113
CPC分类号: C12N15/113 , C12N15/1137 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/344 , C12N2310/3515 , C12N2310/3521
摘要: The invention relates to double-stranded ribonucleic acid (dsRNA) targeting an APOC3 gene, and methods of using the dsRNA to inhibit expression of APOC3.
-
7.
公开(公告)号:US11932854B2
公开(公告)日:2024-03-19
申请号:US17510277
申请日:2021-10-25
发明人: Mark Cancilla , James John Cunningham , William Michael Flanagan , Henry J. Haringsma , Denise M. Kenski , Matthew G. Stanton , Steven M. Stirdivant , Aarron T. Willingham
IPC分类号: C07H21/02 , A61K31/713 , C12N15/11 , C12N15/113
CPC分类号: C12N15/113 , A61K31/713 , C07H21/02 , C12N15/111 , C12N2310/14 , C12N2310/315 , C12N2310/321 , C12N2310/3231 , C12N2310/331 , C12N2310/344 , C12N2310/346 , C12N2310/351 , C12N2320/32 , C12N2320/51 , C12N2310/321 , C12N2310/3527 , C12N2310/321 , C12N2310/3521 , C12N2310/322 , C12N2310/3533
摘要: The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (siNA) molecules that are capable of mediating or that mediate RNA interference (RNAi) against target gene expression.
-
公开(公告)号:US20240018517A1
公开(公告)日:2024-01-18
申请号:US18036473
申请日:2021-11-12
发明人: David T. SCADDEN , Youmna KFOURY
IPC分类号: C12N15/113 , C12N5/0789 , A61P31/10 , A61K31/7105
CPC分类号: C12N15/113 , C12N5/0647 , C12N2320/30 , A61K31/7105 , C12N2310/344 , A61P31/10
摘要: The invention features a method of treating a disease or disorder in a subject, the method comprising administering a therapeutically effective amount of a 5′-tiRNA to treat the disease or disorder in the subject.
-
9.
公开(公告)号:US11873489B2
公开(公告)日:2024-01-16
申请号:US16763399
申请日:2018-11-13
IPC分类号: C07H21/02 , C12N15/113
CPC分类号: C12N15/113 , C12N2310/141 , C12N2310/313 , C12N2310/315 , C12N2310/344 , C12N2310/351 , C12N2330/30
摘要: The present invention relates to products and compositions and their uses. In particular the invention relates to nucleic acid products that interfere with target gene expression or inhibit target gene expression and therapeutic uses of such products.
-
公开(公告)号:US11873485B2
公开(公告)日:2024-01-16
申请号:US17584237
申请日:2022-01-25
发明人: Lisa Hochrein , Mikhail H. Hanewich-Hollatz , Zhewei Chen , Heyun Li , Shashank Gandhi , Marianne Bronner , Niles A. Pierce
CPC分类号: C12N15/11 , C12N9/22 , C12N2310/15 , C12N2310/20 , C12N2310/344 , C12N2310/531 , C12N2310/532 , C12N2800/80
摘要: Programmable guide RNAs (gRNAs) play a central role in the CRISPR revolution sweeping biology and medicine by directing the function of a Cas protein effector to a target gene of choice. To achieve programmable control over regulatory scope, the activity of a conditional guide RNA (cgRNA) depends on the presence or absence of an RNA trigger, allowing for cell-selective regulation of CRISPR/Cas function. Unlike a standard gRNA, a cgRNA is programmable at multiple levels, with the target-binding sequence controlling the target of Cas activity (edit, silence, induce, or bind a gene of choice) and the trigger binding sequence controlling the scope of Cas activity. cgRNA mechanisms that are allosteric allow for independent design of the target and trigger sequences, providing the flexibility to select the regulatory target and scope independently. Disclosed herein are allosteric cgRNA mechanisms for both ON→OFF logic (conditional inactivation by an RNA trigger) and OFF→ON logic (conditional activation by an RNA trigger). Allosteric cgRNAs enable restriction of CRISPR/Cas function to a desired cell type, tissue, organ, or disease state. Allosteric cgRNAs provide a versatile platform for cell-selective and tissue-selective research tools, biotechnologies, diagnostics, and therapeutics.
-
-
-
-
-
-
-
-
-